Two-Drug attack on tough melanoma shows promise in early trial
NCT ID NCT03021460
First seen Jan 22, 2026 · Last updated May 01, 2026 · Updated 12 times
Summary
This early-phase study tested a combination of two drugs—pembrolizumab (an immunotherapy) and ibrutinib (a targeted therapy)—in 20 people with advanced melanoma that could not be surgically removed. The main goal was to find the safest dose of ibrutinib when used with pembrolizumab and to see if the combination could shrink tumors. The study is no longer recruiting, and results will help guide future research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III CUTANEOUS MELANOMA AJCC V7 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.